300357 Zhejiang Wolwo Bio-Pharmaceutical
- 25.20
- -0.39-1.52%
Zhejiang Wolwo Bio-Pharmaceutical News
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Is Going Strong: Have Financials A Role To Play?
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) has had a great run on the share market with its stock up by a significant 14% over the last month. We wonder if and what role the company's financial
Obu Biology (300357.SZ): Currently, the stem cell drug being developed by the company's subsidiary is in the preclinical research stage, and it is impossible to predict the time of industrialization
Gelonghui, May 10 | Our Wu Biology (300357.SZ) said on the investor interactive platform that the indications for stem cell drug research projects can be reviewed in advance. Furthermore, innovative drug development has the characteristics of long cycle, large investment, and high uncertainty. Currently, stem cell drugs being developed by the company's subsidiaries are in the preclinical research stage, and it is impossible to predict the time for industrialization.
Waku Biotech (300357.SZ): Does not involve diabetes-related indications
Gelonghui, May 9丨Our Wu Biology (300357.SZ) said on the investor interactive platform that the company's subsidiary's stem cell drug research project is currently in the preclinical research stage and does not involve diabetes-related indications.
Are Investors Undervaluing Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) By 24%?
Key Insights Zhejiang Wolwo Bio-Pharmaceutical's estimated fair value is CN¥30.47 based on 2 Stage Free Cash Flow to Equity Zhejiang Wolwo Bio-Pharmaceutical is estimated to be 24% undervalued based
Wowu Biotech (300357.SZ): Net profit of 310 million yuan in 2023, plans to distribute 10 to 1.85 yuan
Gelonghui, April 18 | WuWu Biotech (300357.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 848 million yuan, a year-on-year decrease of 5.34%; net profit attributable to shareholders of listed companies was 310 million yuan, a year-on-year decrease of 11.06%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 298 million yuan, a year-on-year decrease of 5.20%; basic earnings per share were 0.5924 yuan; it plans to distribute a cash dividend of 1.85 yuan (tax included) to all shareholders for every 10 shares.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Price Dropped 5.6% Last Week; Private Companies Would Not Be Happy
Key Insights Zhejiang Wolwo Bio-Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 3 investors
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 29% Price Boost Is Out Of Tune With Earnings
Those holding Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) shares would be relieved that the share price has rebounded 29% in the last thirty days, but it needs to keep going to repair th
Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
0.4% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Shareholders Over That Period
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of Zhejiang Wolwo Bio-Pharma
Obu Biology (300357.SZ): Stem cell therapy is currently in the preclinical research stage
Gelonghui January 24 丨 Our Wu Biology (300357.SZ) was surveyed by a specific target on January 24, 2024, about “How is the development progress of the company's stem cell products?” The company replied that the company's stem cell therapy is currently in the preclinical research stage and has not submitted an application for clinical trials.
Pinning Down Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) P/E Is Difficult Right Now
With a price-to-earnings (or "P/E") ratio of 48x Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) may be sending bearish signals at the moment, given that almost half of all companies in Chin
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
With its stock down 5.6% over the past month, it is easy to disregard Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357). However, a closer look at its sound financials might cause you to think again.
Does Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Market Cap Surged CN¥974m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Key Insights Significant control over Zhejiang Wolwo Bio-Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions A
[Instant Analysis of BT Financial Report] WuWu Biotech 2023 Third Quarter Report: Total Assets Increased by 14.23%, Net Profit Decreased by 17.44%
Announcement time of this financial report: 2023-10-25 16:31:31 WuWu Biotech (stock code: 300357) is a company operating in the biomedical industry and is committed to developing and producing high-quality biomedical products. The company adheres to the concept of innovation and R&D, has advanced technology and equipment, and maintains close cooperation with domestic and foreign research institutions and partners. In terms of policy changes in China's pharmaceutical industry, the company is responding positively and continuously improving its R&D capabilities and product quality to meet changes in market demand. First, from the perspective of balance and liabilities, WuWu Biotech for the third quarter of 2023
WuWu Biotech (300357.SZ) released results for the first three quarters, with net profit of 270 million yuan, a decrease of 17.44%
Wuwu Biotech (300357.SZ) released its report for the third quarter of 2023, and achieved operating income of 6.7 in the first three quarters...
1.6% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Shareholders Over That Period
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret to
WuWu Biotech (300357.SZ): Obtaining a summary report of the phase I clinical trial of dermatitis diagnostic patch 01 patch
Gelonghui, September 27丨WuWu Biotech (300357.SZ) announced that recently, the “Dermatitis Diagnostic Patch 01 Patch” developed by Zhejiang Wowu Biotechnology Co., Ltd. completed “a clinical study exploring the tolerance of dermatitis diagnostic patch 01 patch among healthy Chinese volunteers” and obtained a summary report on the phase I clinical trial. The safety evaluation results showed that the adverse events in the four dose groups set up in this study were all mild (grade 1) and moderate (grade 2), and there were no adverse events or serious adverse events leading to withdrawal; the average irritation score of potassium dichromate membranes was higher than that of nickel sulfate films, cobalt chloride membranes,
Wawu Biotech (300357.SZ): The first subject of the phase I clinical trial of Aspergillus fumigerum prick was enrolled
Wuwu Biotech (300357.SZ) announced that the “Aspergillus fumigerum prick solution” developed by the company was treated in Tongji, Huazhong University of Science and Technology...
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) has had a rough month with its share price down 16%. However, a closer look at its sound financials might cause you to think again. Given that fundame
Analysis
Price Target
No Data
